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ABSTRACT Alzheimer disease (AD) is characterized pathologically by extracellular amyloid deposits
composed of Ab peptide, neurofibrillary tangles (NFTs) made up of hyperphosphorylated tau, and a deficit
of cholinergic neurons in the basal forebrain. Presently, only symptomatic therapies are available for the
treatment of AD and these therapies have a limited time frame of utility. Amyloid disorders represent the
effects of chronic Ab production and are not a secondary pathological effect caused by a distant trigger;
therefore targeting Ab is a viable pursuit. In this review, we will discuss the various small molecule anti-
aggregation inhibitors that have been reported in the literature, with emphasis on compounds that are
presently being investigated in clinical trials. Drug Dev Res 70 : 111–124, 2009. r 2009 Wiley-Liss, Inc.
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INTRODUCTION
An enormous amount of evidence, much of which
materialized from analyzing hereditary forms of Alzhei-
mer’s disease (AD), share the consensus that Ab
aggregation is important in disease propagation [Hardy
and Selkoe, 2002]. However, controversy still exists as to
whether the fibrils are indeed a cause or a consequence
of the disease. Ab aggregation is an intricate process and
appears to entail more than a simple conversion of
soluble monomer to fiber. In addition, despite many
mutations in the amyloid precursor protein (APP) gene
associated with early onset of AD, the levels of amyloid
deposited in the brain do not equate with disease
severity. A likely explanation for the occurrence is that
the b-structured prefibrillar species, soluble amyloid
oligomers or prefibrillar aggregation intermediates, are
the primary toxic species in degenerative amyloid
diseases (Fig. 1) [Glabe, 2005; Hardy and Selkoe,
2002]. Most importantly, it is clear that the most crucial
factor determining Ab toxicity is the aggregation state.
Further, it remains to be determined whether the
oligomers that appear transiently at different stages
during fibrillization are simply intermediates on the
pathway leading to fibril formation, or whether they
represent ‘‘off pathway’’ aggregates that populate an
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alternative aggregation pathway [Gorman et al., 2003]. If
Ab oligomers are simply intermediates on the pathway
to fibril formation, then inhibitors that prevent oligomer
formation would also be expected to prevent amyloid
formation. However, if fibrils and oligomers represent
distinct aggregation pathways, then some inhibitors
would block Ab oligomerization but not necessarily
fiber formation or vice versa. Using an oligomer-specific
antibody, A11, to detect oligomer formation, Necula and
workers [Necula et al., 2007] investigated the mechan-
isms for action of a large panel of small molecules that
had previously been reported to inhibit the aggregation
and toxicity of different amyloidogenic proteins. The
A11 antibody recognizes Ab oligomers and protofibrils
greater than 40 KDa in size but does not react with
monomeric Ab, fibrillar Ab, or the amyloid precursor
protein [Kayed et al., 2003]. Depending on the ability of
the small molecules to modulate Ab42 aggregation into
oligomers and/or fibers, the compounds were divided
into three subsets. These data indicated that soluble
oligomers are not obligate intermediates for fibril
formation and that oligomers and fibrils belong to two
distinct aggregation pathways. It is worthwhile to note
that this does not necessarily suggest that oligomers do
not ultimately form fibrils, as there is possibly more than
one pathway leading to Ab fibril formation. Oligomers
may also constitute an ‘‘off pathway’’ assembly state
whereby they themselves do not necessarily convert into
fibrils but are present to maintain the concentration of
monomers that in due course convert into fibrils.
Aggregation of Ab initiates a series of events that
ultimately results in neuronal death, as well as cognitive
and behavioral decline that is characteristic of AD.
Consequently, compounds that inhibit Ab aggregation,
fibrillization, and/or plaque formation may be capable
of protecting neurons from Ab toxicity and thus display
therapeutic potential for the disease. For these reasons,
a quest began to discover small molecules that may
intercede with the in vitro or in vivo aggregation and/or
neurotoxicity of Ab peptides.
SYNTHETIC PEPTIDES, b-SHEET BREAKER PEPTIDES
D-Analogues and Disrupting/Recognition Elements
Because Ab is self-assembling, the first strategy in
developing Ab aggregation inhibitors was to target the
peptide sequence itself by using short peptide frag-
ments homologous to the full-length wild-type protein.
Fig. 1. Summary of amyloid assembly mechanism. In disease states, proteins that normally exist as soluble monomers undergo aggregation to
form various intermediates consisting of unstructured aggregates or amyloidogenic species. Amyloidogenic oligomers subsequently assemble to
generate insoluble fibrils that accumulate in the affected tissues or organs. Compounds that inhibit formation of these undesirable species may,
therefore, be capable of protecting tissues or organs from their toxic effects. [Color figure can be viewed in the online issue which is available at
www.interscience.wiley.com]
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In the hopes of developing a lead compound against
amyloid formation, one of the first groups to make use
of a homologous section of Ab as a structural starting
element was Tjernberg et al. who identified Ab (16–20)
(KLVFF), which bound to the full-length Ab and
prevented assembly into fibrils [Tjernberg et al., 1996].
Inhibition of aggregation by this small Ab fragment was
controlled through recognition of KLVFF to the
identical sequence within full-length Ab via hydro-
phobic and electrostatic interactions [Watanabe et al.,
2001]. Slightly longer peptides containing this
sequence or those with D-amino acid analogues, lflrr
and yflrr, were subsequently synthesized and inhibited
fibril formation [Tjernberg et al., 1997, 1998].
Simultaneously, Soto and co-workers also began
work on peptide inhibitors aimed at the core region of
Ab, specifically residues 17–21 (LVFFA) [Soto et al.,
1996, 1998]. Peptides with partial homology to the
central 17–21 region of Ab but with proline replace-
ments at key positions were observed to convert Ab
fibrils to amorphous aggregates and inhibit Ab toxicity
in vitro and in vivo [Soto et al., 1996, 1998]. Proline
substitutions were introduced for their propensity to
inhibit the b-structure of hydrophobic peptides, and
resulted in peptides with a greater capacity to inhibit
fibril formation (e.g., RDLPFFDVPID and LPFFD).
Furthermore, the pentapeptide reduced the extent of
IL-1-positive microglial cells surrounding amyloid
deposits in vivo [Sigurdsson et al., 2000]. Hughes
et al. [1996] reported that substitution of the two Phe
residues located at positions 19 and 20 in the
octapeptide (QKLVTTAE) could also inhibit fibril
formation by approximately 10-fold, although this was
the result of only weak interactions between the
octapeptide and monomeric Ab.
To improve the efficacy of the peptide inhibitors,
Soto et al. [1998] developed all D analogs of these
peptides, which were just as effective in inhibiting fibril
formation, though with increased protease resistance.
These so-called ‘‘b-sheet breaker peptides’’ were stable
in vivo and exhibited blood-brain barrier permeability,
but have yet to progress to human clinical trials
[Poduslo et al., 1999; Soto et al., 1998].
An alternative approach to the design of inhibi-
tors of amyloid toxicity has involved the use of a
recognition element, which serves to interact specifi-
cally with Ab, linked to a disrupting element, which
interferes with normal fibril self-assembly and alters Ab
aggregation pathways. Many of the disrupting elements
were based on variants of b-sheet breaker peptides,
such as KKKKK or EEEEE [Lowe et al., 2001] or
adding amino acids DD [Watanabe et al., 2002]. The
anti-aggregant properties of peptide inhibitors, gener-
ated using this approach, have been well documented
[Ghanta et al., 1996; Lowe et al., 2001; Miyamura et al.,
2006; Pallitto et al., 1999].
Ghanta and co-workers designed a prototype
peptide inhibitor with a recognition element homo-
logus to the Ab peptide, 15–25, linked to a lysine
hexamer as the disrupting element at the C-terminus
[Ghanta et al., 1996]. The peptide modified Ab
aggregation kinetics and protected cells from
Ab-induced toxicity. Furthermore, residues 16–20 in
Ab (KLVFF) were more effective as a recognition
element than 15–25, and demonstrated increased
efficacy against cytotoxicity [Pallitto et al., 1999]. The
scrambled sequence VLFKF was observed to also
be just as effective as KLVFF, suggesting that it is the
overall hydrophobicity rather than the specific amino
acid sequence that is essential. Surprisingly, none of the
hybrid inhibitors from the study could prevent Ab
aggregation; rather, they increased aggregate size and
changed aggregate morphology. These results strongly
suggest that compounds need not prevent aggregation
to stop Ab toxicity. Furthermore, the hybrid inhibitors
might work via a mechanism that does not rely on a 1:1
complex with Ab. Collectively, these studies offer
evidence that molecules that can interact with Ab
may interfere with its aggregation and result
in inhibition of Ab-induced pathological readout
measures.
N-Methylated Peptides
Peptide N-methylation has also emerged as a
powerful tool for inhibition of Ab and a mechanism to
improve peptide half life in vivo [Bodles et al., 2004;
Gordon and Meredith, 2003; Gordon et al., 2001;
Hughes et al., 2000; Kapurniotu et al., 2002; Kokkoni
et al., 2006; Yan et al., 2006]. N-methylation is known
to lock the residues into a b conformation [Manavalan
and Momany, 1980], generating soluble monomeric
b-sheet peptides [Doig et al., 1997]. N-Methylated
peptides or ‘‘meptides’’ function by binding to the face
of the aggregating peptide through the amide NH
groups at the outer edges of the b sheet, effectively
blocking intermolecular hydrogen bonding, thus re-
sulting in the prevention of both aggregation and
toxicity. Substituents larger than methyl groups [Rijkers
et al., 2002] are also effective as inhibitors of
amyloidosis.
Hughes and co-workers demonstrated that
N-methylated derivatives of Ab25–35 were capable of
preventing the aggregation and inhibiting the toxicity of
the wild type full-length Ab peptide [Hughes et al.,
2000]. The N-methylated derivatives of Ab25–35
in isolation were soluble and non-toxic because
N-methylation blocked hydrogen bonding on the outer
edge of the assembling aggregates. Specifically, Ab25–35
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with N-methylated Gly33 or Leu34 inhibited fibril
assembly entirely and decreased the toxicity of
aggregated amyloid.
Gordon and coworkers investigated N-methylated
peptides of a region corresponding to 16–22 and later
16–20 of the amyloid ‘‘core domain’’ region to examine
their ability to prevent Ab fibril formation and
disassemble preformed fibrils [Gordon et al., 2001,
2002]. Not only did these peptides display high
proteolytic resistance, solubility, and membrane per-
meability [Gordon et al., 2002], they also exhibited
a high propensity to form b-structures at the
N-methylated site. Cruz and coworkers demonstrated
that single N-methyl amino acid-containing peptides
similar to 16–20 of Ab could also reduce the
cytotoxicity of Ab42 [Cruz et al., 2004].
The use of specific peptides to inhibit Ab
aggregation and toxicity, although intriguing, has
yet to progress beyond in vivo models of amyloidosis.
The use of such compounds as molecular markers for
the presence of Ab aggregates has also been suggested
as a more viable use for these peptide inhibitors
[Esteras-Chopo et al., 2008; Wiesehan et al., 2008]
Small Molecule Inhibitors Based on Amyloid Dyes
Aside from the sequence-based drug design
described above, small molecule inhibitors of Ab
aggregation have been modeled based on the histolo-
gical dyes used to characterize amyloid both in vitro
and in vivo. One class of candidates is based on the
sulfonated dyes including Congo red, chrysamine G,
and thioflavin S. Congo red was reported to inhibit
fibrillization and neurotoxicity of Ab [Fraser et al.,
1992; Lorenzo and Yankner, 1994]. Unfortunately, this
dye cannot cross the blood-brain barrier and is
carcinogenic if given orally, thereby hindering its
therapeutic use [Frid et al., 2007]. Due to abundant
data supporting the beneficial effects of Congo red
interactions with Ab, the search for a Congo red
congener was undertaken. For example, chrysamine G,
a smaller and more lipophilic variant of Congo red, has
been shown to cross the blood-brain barrier and can
block the formation of Ab fibrils, reduce Ab toxicity,
and increase Ab proteinase digestion [Klunk et al.,
1998].
Aside from Congo red or chrysamine G, other
sulfonated dyes can also attenuate the toxic effects of
Ab [Pollack et al., 1995b]. However, those compounds
need to adopt a conformation whereby the two
sulfonate groups that must be at a similar distance to
that displayed in Congo red. This demand implicates a
very precise interaction that must occur between the
negatively charged sulfonate groups and Ab for
efficacy. Recently, three structural features have been
discovered as necessary for an effective and potent
inhibitor to Ab [Reinke and Gestwicki, 2007]. First, a
second terminal phenyl group must be present in the
inhibitor compound that interacts with Ab, as it is
essential for activity. Ligands that contain simple
aromatics failed to be active against Ab. Second, a
hydroxyl substitution on the aromatic end group in the
compound is also important for inhibition, as loss of the
hydroxl group on the aromatic rings abolished inhibi-
tory activity. Finally, ligands must contain linkers
between 8A˚ and 16A˚ in distance, and need to be rigid
with less than one to two freely rotating carbons. Congo
red and chrysamine G are two successful Ab inhibitors
that meet all three of the structural requirements
[Masuda et al., 2006; Necula et al., 2007; Porat et al.,
2006; Yang et al., 2006]. Of the most significant features
is the linker component, as even compounds that
conform to the other sub-structural pre-requisites,
including aromatic substitutions, failed to inhibit if a
short linker is present. A ‘‘Goldie-Locks’’ model was
proposed, whereby both the length and flexibility of the
linker equally contribute to defining the optimal range
and potency of the ligand.
Although dye-based therapeutics have so far not
reached clinical trials, these compounds have found
application in imaging methodologies [Mathis et al.,
2007] and are being investigated in a number of
imaging techniques, such as magnetic resonance
spectroscopy, position tomography, and single-photon
emission computed tomography. The selectivity of
these compounds for b-sheet-containing fibers has led
to the investigation of these compounds for monitoring
the progression of disease in vivo and for distinguishing
potential therapeutic effects. At present, the following
compounds are in various phases of clinical trials,
including [11C]-PiB, a thioflavin analogue, BSB, a
Congo red analog, and FSB, a styrylbenzene derivative
(www.clinicaltrials.gov). These compounds have a high
affinity for amyloid, readily cross the blood-brain
barrier, and are presently being used to develop
methodologies for AD diagnosis and for monitoring
of potential treatments.
Metal Chelators
The role of metal ions, notably Cu21 and Zn21, in
AD and metal chelators as therapeutic agents has been
the topic of attention during recent years [Bush, 2003;
Caragounis et al., 2007; Doraiswamy and Finefrock,
2004; Gnjec et al., 2002; Raman et al., 2005; White
et al., 2006a]. Cu21 decreased Ab deposits in APP23
transgenic mice [Bayer et al., 2003] and Ab levels were
reduced by a mutant Cu21 transporter [Phinney et al.,
2003]. Additionally, overexpression of human Ab
peptides in transgenic mice decreased brain Cu21
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[Maynard et al., 2002]. APP knock-out mice also
displayed elevated levels of Cu21 [White et al., 1999].
Although many reports have ascribed a major role for
metal ions in AD, a substantial amount of research has
also pointed to the deleterious effects of metal ions in
the development of AD. While these metals are
essential in most biological reactions, their excessive
accumulation can be cytotoxic, as an imbalance in
metal homeostasis can result in a vast range of cellular
disturbances typified by oxidative stress and elevated
levels of superoxide or free radical production.
Precipitation and aggregation of Ab peptides to form
senile plaques and NFTs have been documented
[Fisher and Naughton, 2005].
The biochemical mechanisms by which metal
ligands affect Ab metabolism has been of great interest.
The anti-malarial 8HQ (8-hydroxyquinoline) derivative
5-chloro-7-iodo-8-hydroxyquinoline (CQ; clioquinol), is
a transition metal ion chelator [Di Vaira et al., 2004;
Lane et al., 1960]. CQ can dissolve plaque deposits of
AD brain tissue in vitro [Bush, 2003], and decrease
deposits in animal AD models. [Bush, 2003; Cherny
et al., 2001]. CQ-metal complexes can also up-regulate
matrix metalloprotease (MMP) activity in vitro by
activating phosphoinositide 3-kinase (PI3K) and c-jun
N-terminal kinase (JNK). Enhanced MMP activity
increased degradation of secreted Ab peptide [White
et al., 2006b].
Caragounis et al. [2007] studied different classes
of metal ligands that increase cellular metal levels,
showing that Cu21 and Zn21 resulted in considerable
loss of secreted Ab. The metal ligands that reduced Ab
levels included 8HQ (8-hydroxyquinoline) and phe-
nanthroline derivatives, as well as the sulfur compound
PDTC (pyrrolidine dithiocarbamate). The authors
speculated that the inhibitory affect was due to a
higher lipid solubility of the ligands and their ability to
enhance metal uptake. However, it was also possible
that the ligands could effectively inhibit Ab levels
without altering cellular metal homeostasis [Treiber
et al., 2004; White et al., 2006a]. These results suggest
that a host of metal ligands can have analogous results
on Ab turnover, with a number of lipid-soluble ligands
significantly decreasing extracellular levels of Ab once
complexed to Cu21 or Zn21. This reduction could be
attained through metal-dependent activation of JNK
and upregulation of MMP activity, and, as a result, an
up-regulation of metalloprotease activity and conse-
quent loss of secreted Ab.
CQ administration to AD patients dramatically
reduced progression of cognitive decline and coincided
with a decrease in plasma Ab42 levels [Ritchie et al.,
2003]. While CQ was of interest as a potential drug
[Bush, 2003; Ritchie et al., 2003; Yassin et al., 2000] for
AD treatment, its evaluation has been discontinued
due to deleterious side effects in Japanese patients and
efforts have been focused on novel, non-toxic con-
geners of CQ. A third-generation clioquinol, PTB2, has
finished a small Phase IIa clinical trial in early AD
patients (www.pranabio.com). PBT2 had a good safety
and tolerability profile, and at a high dose reduced
cerebrospinal fluid Ab42 levels compared to placebo.
These results supported the in vivo findings in a
transgenic mouse model of AD, where PBT2 reduced
toxic oligomers of Ab, reversed Ab-induced loss of
neurotransmission and improved cognition (www.
pranabio.com). The ultimate efficacy and safety profile
of this class of compounds will await further human
clinical trial data.
Polyphenols
Polyphenols are a large group of synthetic and
naturally occurring small molecules that are composed
of one or more aromatic phenolic rings and are
divided into three main groups, including phenolic
acids, flavonoids, and non-flavonoid polyphenols
[Ramassamy, 2006]. Experimental and epidemiological
evidence suggests that natural polyphenolic com-
pounds, such as those found in teas, berries, fruits,
spices, and plants, have antioxidative, anti-inflamma-
tory, and anti-aggregant properties. Given the multi-
faceted nature of Ab-related neurotoxicity, much work
has been done to examine both the direct interaction of
polyphenols on Ab fibrillogenesis and on secondary
effects, such as Ab-induced pro-apoptotic mechanisms.
As over 8,000 polyphenolic compounds are known, this
discussion will focus on the interaction between
amyloid peptides and three well-characterized natu-
rally occurring phytochemicals; curcumin, ()epigallo-
cathechin-3-gallate, and Ginkgo biloba (Fig. 2).
Curcumin
Epidemiological studies indicating a significantly
lower prevalence of AD in the Asian Indian population
compared to the United States suggest the possibility of
a dietary correlation [Ganguli et al., 2000; Ramassamy,
2006]. The common use of tumeric as a curry spice has
pointed to its main constituent, curcumin, as a possible
mediator of anti-Ab effects. Indeed, curcumin and
related compounds like calebin-A, dimethoxycurcumin,
and bidemethoxycurcumin, inhibit fibril formation and
extension and promote destabilization of pre-aggre-
gated Ab peptides [Kim et al., 2005; Ono et al., 2004;
Park and Kim, 2002; Yang et al., 2005]. Examination of
the structure-activity function of curcumin has identi-
fied three important molecular features, including a
hydroxyl substitution on the aromatic end group, a
narrow linker length between 8–16 A˚, and the presence
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of a second terminal phenyl group that determines its
anti-aggregant properties [Reinke and Gestwicki,
2007]. In vitro, curcumin protects against Ab-induced
death of PC-12, SH-SY5Y neuroblastoma, and human
umbilical vein endothelial cells, via anti-oxidant actions
[Baum and Ng, 2004; Kim et al., 2001; Park and Kim,
2002; Yang et al., 2005]. Not surprisingly, intrave-
nously-injected curcumin binds to parenchymal and
vascular amyloid deposits in the brains of TgAPPswe/
PS1 and Tg2576 mice [Garcia-Alloza et al., 2007; Yang
et al., 2005]. Additionally, promising anti-amyloid
effects have also been noted in TgAPP mice fed with
varying doses of curcumin. For instance, Lim et al.
[2001] reported decreased concentrations of soluble
and insoluble Ab40 and Ab42 peptides, an amelioration
of plaque burden, decreased amounts of oxidized
proteins, and lower interleukin-1b (IL-1b) levels in
the brains of 10-month-old TgAPPswe mice fed
curcumin for 6 months. Similar effects were also noted
in 17-month-old Tg2576 mice, suggesting the effec-
tiveness of curcumin in clearing pre-existing plaques in
vivo [Yang et al., 2005]. In addition, administration of
curcumin to adult rats injected with Ab42 showed
improved performance on the Morris water maze and
an 80% reduction of plaque load throughout the brain,
which correlated with a reversal of Ab-induced
decreases in post-synaptic density 95 protein levels
[Frautschy et al., 2001]. Collectively, these findings
suggest that the neuroprotective capabilities of curcu-
min result from its ability to directly alter the kinetics
of Ab fibrillization, as well as its antioxidative and anti-
inflammatory properties. Curcumin is currently the
focus of two clinical trials in China and the United
States for the evaluation of its effectiveness in AD
patients.
()-Epigallocatechin-3-Gallate
Catechins are a family of plant-derived flavan-3-ols
comprised of ()-epicatechin, ()-epigallocatechin,
()-depicatechin-3-gallate, and ()-epigallocatechin-
3-gallate (EGCG). EGCG is the major polyphenolic
component of green tea and has been implicated in the
prevention of age-related neurodegenerative disorders
such as AD. A variety of experimental in vitro cell
culture paradigms have shown micromolar concentra-
tions of EGCG to be protective against Ab-induced cell
death [Bastianetto et al., 2006; Kim et al., 2007; Levites
et al., 2003]. Further, i.p. and intracerebroventricular
administration of EGCG to Tg2576 mice decreases
soluble and insoluble levels of Ab40 and Ab42 and
Fig. 2. Schematic of the chemical structure of curcumin (A), ()epigallocatechin-3-gallate (B), Ginkgolides (C, left) and bilobalides (C, right).
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reduces plaque load by 40–50% across the hippocam-
pus and cortex of treated animals [Rezai-Zadeh et al.,
2005]. A variety of mechanisms, including anti-
aggregation, anti-inflammatory, antioxidative, and
iron-chelating capabilities have been proposed to
mediate these neuroprotective effects [Bastianetto
et al., 2006; Kim et al., 2007; Levites et al., 2003;
Obregon et al., 2006; Rezai-Zadeh et al., 2005;
Reznichenko et al., 2006]. For instance, EGCG
treatment induced an upregulation in pro-survival
mitogen activated protein kinase (MAPK) phospha-
tase-1 levels and antagonized Ab/IL-1-induced
p38MAPK and JNK phosphorylation [Kim et al., 2007].
EGCG also appears to inhibit Ab toxicity by
promoting non-amyloidogenic APP processing. Treat-
ment of human SH-SY5Y neuroblastoma and N2aswe
cells with EGCG induced a dose- and time-dependent
increase in the levels of sAPPa and secreted a-C-
terminal fragment (CTF), without altering holo-APP
expression [Levites et al., 2003; Rezai-Zadeh et al.,
2005]. In addition, EGCG administration increased the
expression of two putative a-secretases, TACE and
ADAM-10, correlating with increased levels of aCTF
and sAPPa and decreased concentrations of Ab40 and
Ab42. This effect was abolished in the presence of the
a-secretase inhibitor, Ro31-9790, or following
ADAM-10 siRNA knockdown [Levites et al., 2003;
Obregon et al., 2006; Rezai-Zadeh et al., 2005].
Furthermore, EGCG dose-dependently inhibits BACE1
activity in vitro [Jeon et al., 2003]. Collectively, these
results indicate that the neuroprotective effects of
EGCG and other green tea catechins are due, at least
in part, to the ability of EGCG to directly modulate APP
processing and to counteract the pro-inflammatory and
pro-oxidative cellular environment induced by Ab
exposure.
Gingko Biloba
Gingko biloba extracts have been used for
centuries in traditional Chinese medicine for their
antioxidant and anti-apoptotic effects. The standar-
dized concentrated extract, EGb-761, contains a
mixture of 27% flavonols (e.g., quercetin, kaempferol,
and isorhamnetin) and 6–7% terpene lactones (e.g.,
bilobalide and gingkolides A, B, and C) [Augustin et al.,
2008; Ramassamy, 2006; Vitolo et al., 2007]. Both EGb-
761 and its constituents have been investigated for
their neuroprotective properties against Ab-induced
toxicity. Treatment with EGb-761 and its flavonoid
fraction CP205 rescues N2a, PC-12, and primary mixed
hippocampal cell cultures from Ab-stimulated apopto-
sis by counteracting elevations in reactive oxygen
species, and preventing NF-kB activation [Bastianetto
et al., 2000; Longpre et al., 2006; Yao et al., 2001]. Such
anti-inflammatory and antioxidative properties might
account in part for the protective effects of ginkgolides
A, B, and J in reducing Ab42-induced decreases in
synaptophysin levels and restoring long-term potentia-
tion in hippocampal slice cultures [Bate et al., 2008;
Vitolo et al., 2007]. Recent in vivo findings have shown
that treatment with Gingko biloba or EGb-761
improves motor performance and rescues spatial
memory impairments in APP transgenic Caenorhabdi-
tis elegans worms and Tg2576 mice [Stackman et al.,
2003; Tchantchou et al., 2007; Wu et al., 2006]. In most
cases, EGb-761 treatment decreased the level of
20–28 kDa Ab oligomers, without affecting APP
transgene expression [Tchantchou et al., 2007; Wu
et al., 2006].
Recently, it has also been reported that BACE1
mRNA levels and activity were not altered in EGb-761-
treated N2a cells, nor in Tg2576 mice receiving
EGb-761 over a 4-week period [Augustin et al.,
2008]. Furthermore, EGb-761 treatment did not affect
levels of ADAM10 or ADAM17 in rats given EGb-761,
despite an upregulation of sAPPa expression [Colciaghi
et al., 2004]. These data suggest that EGb-761 inhibits
Ab fiber growth directly, rather than by acting upon
APP secretase activity. This hypothesis is supported by
in vitro findings that EGb 761 and CP205 were able to
inhibit oligomeric formation of Ab-derived diffusible
soluble ligands (ADDLs) and prevent fibril formation
at low doses [Chromy et al., 2003; Longpre et al., 2006;
Yao et al., 2001]. Gingko in combination with curcumin
is presently in a Phase II trial in Hong Kong, where the
safety and tolerability of these compounds are being
evaluated in AD patients.
Glycosaminoglycan mimetics
Glycosaminoglycans (GAGs) are unbranched
linear polymers of repeated disaccharide units that
attach covalently to a protein core to form proteogly-
cans. Non-sulfated GAGs include hyaluronic acid,
while sulfated GAGs are comprised of chondroitin,
keratan, dermatan, and heparan sulfates [Diaz-Nido
et al., 2002; van Horssen et al., 2003]. The hypersul-
fated form of heparan sulfate is referred to as heparin
[Diaz-Nido et al., 2002]. Chondroitin sulfate, heparan
sulfate, and hyaluronic acid have all been identified in
the developing and mature rodent brain and may be
involved in cell attachment and neurite outgrowth
[Oohira et al., 2000].
An association between GAGs/proteoglycans and
AD has been suggested since the 1850s, when amyloid
deposits in kidney, liver, and spleen were found to
contain carbohydrates [Kisilevsky et al., 2007]. Con-
firmation of a proteoglycan accumulation in AD brain
lesions was provided by Snow and colleagues, who
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demonstrated the presence of sulfated GAGs, pre-
dominantly that of heparan and chondroitin sulfate, in
neuritic plaques, vascular amyloid deposits, and
neurofibrillary tangles [Snow et al., 1988, 1990]. A role
for sulfated GAGs and related proteoglycans in the
formation and/or promotion of Ab deposition has also
been suggested from in vitro and in vivo experiments.
Perlecan, an extracellular matrix-associated heparan
sulfate glycoprotein, binds directly to both Ab40 and
Ab42 and dose-dependently increases the amount, rate,
and stability of fibril formation [Castillo et al., 1997].
Furthermore, binding of heparan sulfate and chon-
droitin sulfate proteoglycans to fibrillar Ab, prevented
its proteolytic degradation, an effect that is blocked in
the presence of free GAG chains [Gupta-Bansal et al.,
1995]. Co-infusion of Ab40 plus heparan sulfate
proteoglycan into the hippocampus of adult rats
significantly increased Ab plaque deposition, compared
to rats injected with Ab40 alone [Snow et al., 1994]. A
direct role for GAGs in Ab fibril formation has been
further suggested by reports that heparin, chondroitin
sulfate A, keratan sulfate, dermatan sulfate, dextran
sulfate, and heparan sulfate are all able to accelerate
fibril nucleation and extension [Castillo et al., 1999;
McLaurin et al., 1999].
Given that fibrillar Ab is now considered to be the
least toxic of the amyloid peptide conformations, it is
perhaps not surprising that GAG-Ab interactions are
neuroprotective. Treatment of rat primary hippocampal
cultures with chondroitin sulfate or heparan sulfate
attenuated Ab-induced neurite fragmentation and
cellular toxicity [Woods et al., 1995]. Administration
of the low molecular weight heparin, enoxaparin, also
dose-dependently inhibited Ab-induced toxicity in PC-
12 neuroblastoma cells [Bergamaschini et al., 2004].
Similarly, highly sulfated GAGs, such as carrageenan-t
pentosan sulfate and heparin sulfate protect against
decreased cell viability caused by Ab in PC-12 cells,
while less sulfated GAGs were less effective [Pollack
et al., 1995a]. The importance of sulfate group number
and distribution on the GAG backbone for the
effectiveness of its interaction with Ab [Fraser et al.,
1992; Leveugle et al., 1994], was confirmed by reports
that heparin-induced increases in Ab fibril formation
were impaired following removal of O- and N-sulfates
and were completely lost upon removal of all sulfate
moieties from heparin [Castillo et al., 1998, 1999].
Further examination of the structure-activity
relationships mediating GAG-Ab binding have led to
the proposal that a cluster of basic amino acids in the
N-terminal region of the Ab peptide (residues 13–16)
affect its secondary structure, thereby influencing the
peptide interaction with GAGs [McLaurin and Fraser,
2000]. In addition, fluorescent spectroscopy and
electron microscopy experiments have demonstrated
that sulfated mono- and disaccharides derived from
chondroitin sulfate bind Ab directly, competing with
intact chondroitin sulfate and heparin for Ab binding
[Fraser et al., 2001]. Furthermore, chondroitin sulfate-
derived disaccharides were sufficient to induce lateral
fiber aggregation and conversion of protofibrils into
mature amyloid fibers [Fraser et al., 2001]. These
results suggested that the development of small,
sulfated compounds that cross the blood-brain barrier
and mimic GAG-Ab binding might be therapeutically
useful for sequestering toxic Ab species.
As such, some GAG-based therapies have been
based on the use of low molecular weight heparin
derivatives, many of which are currently used in the
treatment of venous thromboembolism. Zhu et al.
[2001] reported that pre-treatment with either enox-
aparin or dalteparin arrested the progression of
inflammation-associated amyloid induction by blocking
b-pleated sheet formation. Similarly, Bergamaschini
et al. [2004] demonstrated that chronic (e.g., 6 months)
peripheral administration of enoxaparin to TgAPP23
mice significantly reduced cortical plaque load, de-
creased total Ab40 levels, and attenuated the number of
plaque-associated astrocytes. Interestingly, treatment
of rats with certoparin or its derivative C6, either
before or after intra-amygdaloid infusion of Ab,
blocked Ab-associated changes to intracellular tau
and reduced astrogliosis, without altering Ab aggrega-
tion [Walzer et al., 2002]. Similar findings were also
reported by Dudas et al. [2002] using the C3 derivative,
which protects against Ab-induced increases in tau-2-
immunoreactivity in hippocampal neurons. Another set
of GAG-based anti-amyloidogenic compounds has
been designed according to their ionic properties.
Kisilevsky et al. [1995] reported that oral and ip
administration of poly(vinylsufonate sodium salt), a
small-molecule anionic sulfonate, inhibited splenic Ab
deposition in a mouse model of inflammation-asso-
ciated amyloid induction, under both acute and chronic
conditions. A different GAG mimetic, 3-amino-1-
propanesulfonic acid (Tramiprosate), binds soluble
Ab40 and Ab42 peptides and maintains them in a
random-coil conformation [Gervais et al., 2007].
Treatment of rat neuronal cell cultures or SH-SY5Y
neuroblastoma cells with tramiprosate significantly
attenuated Ab42-induced toxicity. Furthermore, admin-
istration of tramiprosate to TgCRND8 mice reduced
compact plaque load and decreased plasma levels, as
well as soluble and insoluble Ab40 and Ab42 concentra-
tions in the brains of treated mice, compared to control
[Gervais et al., 2007]. Although the behavioral effects
of this compound have not been reported, tramiprosate
has been tested in AD and cerebral amyloid angiopathy
118 HAWKES ET AL.
Drug Dev. Res.
[Aisen et al., 2006; Greenberg et al., 2006]. Phase III
clinical trials in AD did not reach clinical significance in
the cognitive outcomes, but due to the good safety and
tolerability trials, this compound will be marketed as a
neutraceutical (www.bellushealth.com).
Lipid-Based Small Molecule Inhibitors
The interaction of Ab with lipids and cellular
membranes has been known for some time, although
the outcome of this interaction is still controversial.
Lipids have been implicated as potential accelerators of
Ab fibrillogenesis and the target of Ab-induced toxicity
thus propagating pathogenesis. Ab deposition is
initiated in a plasma membrane–bound form resulting
in diffuse plaque formation [Yamaguchi et al., 2000]. In
addition, a ‘‘seeding’’ form of Ab in culture is
membrane associated and dependent on cholesterol
levels [Mizuno et al., 1999]. In vitro studies on isolated
hippocampal membranes have shown that Ab has an
enhanced disordering effect on AD membranes as
compared to age-matched controls [Eckert et al.,
2000]. These studies, in conjunction with the enhanced
Ab association with the cell surface [Burdick et al.,
1997; Yang et al., 1998], have led to speculation that
Ab-cell membrane interactions are important for the
development of amyloid deposits. Understanding Ab
interactions with specific lipid families may lead to the
development of lipid mimetics that could inhibit
membrane interactions and subsequent Ab toxicity.
The interaction of Ab with various classes of
lipids, including glycolipids, cholesterol, and phospho-
lipids, has shown that each lipid family is important and
led to the investigation of a number of potential
treatment strategies. Glycolipids, particularly ganglio-
sides, either inhibit Ab aggregation by stabilization of a
novel a/b conformation [McLaurin et al., 1998] or
promote Ab aggregation [Choo-Smith et al., 1997;
Kakio et al., 2002], as demonstrated by the isolation of
a novel ganglioside-bound Ab species from AD brain
[Yanagisawa and Ihara, 1998; Yanagisawa et al., 1995].
In contrast, acidic phospholipids induce b-struc-
tured aggregates and fibers [McLaurin and
Chakrabartty, 1996; Terzi et al., 1995; Waschuk et al.,
2001]. PEGylated phospholipid nanomicelles interact
with Ab thereby mitigating b-structural transitions,
aggregation, and subsequent neurotoxicity [Pai et al.,
2006]. The interaction of Ab with phosphatidylinositol
produced a dramatic increase in fibrillogenesis that was
inhibited by introduction of phosphate groups present
in the other phosphatidylinositol family members of
lipids [McLaurin et al., 1998]. myo-Inositol, the head
group of phosphatidylinositol, inhibited Ab aggregation
and Ab-induced toxicity [McLaurin et al., 1998]. Since
myo-inositol is a native constituent of the CNS, the
effects of the various inositol stereoisomers on Ab-
aggregation and toxicity were examined [McLaurin
et al., 2000; Nitz et al., 2008] and showed a
stereospecific interaction of inositol with Ab that
required all hydroxyl groups to be in an equatorial
position for maximal activity, the scyllo-inositol isomer
[McLaurin et al., 2000]. scyllo-Inositol administration to
TgCRND8 mice prevented Ab-induced cognitive deficits,
plaque formation, synaptotoxicity, and early death
[McLaurin et al., 2006]. These effects were seen in both
prophylactic and treatment studies. Peripheral adminis-
tration of scyllo-inositol also prevented memory deficits in
an acute rat model of Ab-toxicity [Townsend et al., 2006].
These in vivo effects resulted from the inhibition of Ab
oligomer induced toxicity in the rat, and the prevention of
high molecular weight oligomer formation in the Tg
mouse model of AD. scyllo-Inositol also prevents Ab
oligomer-induced synaptotoxicity in a mouse model of
AD [Shankar et al., 2007]. The benefit of scyllo-inositol
may result from the high CNS bioavailability due to the
constitutive activity of the inositol transporters at the
blood brain barrier [Fenili et al., 2007].
scyllo-Inositol had favorable pharmacokinetics,
safety, and tolerability in a Phase I clinical trial
(www.transitiontherapeutics.com) with Phase II
clinical trials initiated in mild to moderate AD patients
in December 2007 (www.clinicaltrials.gov).
CONCLUSION
Although small molecule anti-aggregant inhibi-
tors have not shown efficacy in clinical trials, such
strategies are approaching proof of concept. Clinical
trials utilizing active immunization have suggested that
removal of Ab from the CNS is possible, but effects on
cognitive function, while suggestive, are unclear. On-
going clinical trials may help to elucidate the full
potential of small molecule therapies to improve the
quality of life of patients with AD.
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